Akoya Biosciences, Inc.
AKYADelisted- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001711933
Akoya Biosciences, Inc. was delisted in 2025; its insiders filed their last Form 4 on Jul 10, 2025; 58 institutions reported holding it in 13F filings for Q2 2025, worth $16.3M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 58
- Q2 2025, −6 vs. previous quarter
- 13F value
- $16.3M
- Reported value at the end of Q2 2025
- Superinvestors holding
- 0
- At the end of Q2 2025
Superinvestors holding AKYA, Q2 2025
No superinvestor reported holding AKYA at the end of Q2 2025.
Latest insider trades
Open-market purchases and sales by Akoya Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 12, 2024 (view filing)4:01 PM ET | Jun 11 | 1 day | McKelligon BrianPresident and CEO | SSale | −7.50K | $2.08 | −$15.6K | −3.2%224.7K after | 10b5-1 |
| Jun 7, 2024 (view filing)9:56 PM ET | Jun 6 | 1 day | McKelligon BrianPresident and CEO | SSale | −7.50K | $2.01 | −$15.1K | −3.2%224.7K after | 10b5-1 |
| Mar 22, 2024 (view filing)5:54 PM ET | Mar 20 | 2 days | McKelligon BrianPresident and CEO | SSale | −7.50K | $4.97 | −$37.2K | −3.1%231.9K after | 10b5-1 |
| Mar 22, 2024 (view filing)5:51 PM ET | Mar 13 | 9 days | McKelligon BrianPresident and CEO | SSale | −7.50K | $4.94 | −$37.0K | −3.1%231.9K after | Amended10b5-1 |
| Dec 20, 2023 (view filing)7:16 PM ET | Dec 19 | 1 day | McKelligon BrianPresident and CEO | SSale | −7.50K | $4.48 | −$33.6K | −4.7%152.6K after | 10b5-1 |
| Dec 14, 2023 (view filing)4:24 PM ET | Dec 12 | 2 days | McKelligon BrianPresident and CEO | SSale | −7.50K | $4.25 | −$31.9K | −4.7%152.6K after | 10b5-1 |
| Nov 22, 2023 (view filing)4:00 PM ET | Nov 20 | 2 days | McKelligon BrianPresident and CEO | SSale | −7.50K | $4.39 | −$32.9K | −4.7%152.6K after | 10b5-1 |
| Sep 11, 2023 (view filing) | Sep 7 | 4 days | Pla FredericChief Operating Officer | PPurchase | +20.0K | $4.60 | +$92.0K | New position20.0K after | 2 lots |
| Jun 12, 2023 (view filing) | Jun 12 | Same day | Ek John FrederickCFO | PPurchase | +20.0K | $5.00 | +$100.0K | New position20.0K after | Duplicate filing |
| Jun 12, 2023 (view filing) | Jun 12 | Same day | Lai Goldman MylaDirector | PPurchase | +20.0K | $5.00 | +$100.0K | New position20.0K after |
Top 10 13F holders, Q2 2025
The largest institutional positions in Akoya Biosciences, Inc. at the end of Q2 2025; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Blue Water Life Science Advisors, LLC | 4,697,785 | $6.11M | 4.83% | 00.0% | Unchanged |
| Oddo BHF Asset Management SAS | 1,892,855 | $2.46M | 0.09% | +1,892,855 | New |
| Vanguard Group Inc | 1,194,127 | $1.55M | 0.00% | −194,073−14.0% | Reduced |
| Paragon Associates & Paragon Associates II Joint Venture | 671,000 | $872.3K | 1.39% | 00.0% | Unchanged |
| Trium Capital LLP | 605,496 | $787.1K | 0.20% | +605,496 | New |
| BlackRock, Inc. | 499,510 | $649.4K | 0.00% | −1,112,492−69.0% | Reduced |
| Geode Capital Management, LLC | 245,665 | $319.4K | 0.00% | −321,317−56.7% | Reduced |
| Peddock Capital Advisors, LLC | 234,720 | $305.1K | 0.07% | 00.0% | Unchanged |
| ExodusPoint Capital Management, LP | 205,320 | $267.0K | 0.00% | +205,320 | New |
| Jane Street Group, LLC | 179,381 | $233.2K | 0.00% | +164,244+1,085.0% | Added |